Distinct survival benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in revascularized coronary artery disease patients according to history of myocardial infarction

Circulation Journal

Volumn 77, Issue 5, 2013, Pages 1242-1252

  Nishino, Tomohiro ^a   Furukawa, Yutaka ^a   Kaji, Shuichiro ^a   Ehara, Natsuhiko ^a   Shiomi, Hiroki ^a   Kim, Kitae ^a   Kitai, Takeshi ^a   Kinoshita, Makoto ^a   Morimoto, Takeshi ^c   Sakata, Ryuzo ^b   Kimura, Takeshi ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin; Coronary artery disease; Myocardial infarction; Outcomes; Revascularization

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876774085     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0963     Document Type: Article

References (26)

1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): The CONSENSUS trial study group. N Engl J Med 1987; 316: 1429-1435.
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: The SOLVD investigators. N Engl J Med 1991; 325: 293-302.
3. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
4. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: The SOLVD investigators. N Engl J Med 1992; 327: 685-691.
5. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial: The SAVE investigators. N Engl J Med 1992; 327: 669-677.
6. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure: The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821-828.
7. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensinconvertingenzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction: The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332: 80-85.
8. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril cardiac evaluation (TRACE) study group. N Engl J Med 1995; 333: 1670-1676.
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
10. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebocontrolled, multicentre trial (the EUROPA Study). Lancet 2003; 362: 782-788.
11. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068.
12. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Iwabuchi M, et al. Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan. Cardiovasc Interv Ther 2011; 26: 234-245.
13. Natsuaki M, Furukawa Y, Morimoto T, Nakagawa Y, Ono K, Kaburagi S, et al. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization: Perspectives from the CREDOKyoto registry cohort-2. Circ J 2012; 76: 1369-1379.
14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR: Revised equation for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
15. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
16. Rutherford JD, Pfeffer MA, Moyé LA, Davis BR, Flaker GC, Kowey PR, et al. Effects of captopril on ischemic events after myocardial infarction: Results of the survival and ventricular enlargement trial: Save investigators. Circulation 1994; 90: 1731-1738.
17. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
18. Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 1999; 33 (Suppl 1): S21-S28; discussion S41-S43.
19. Nguyen Dinh Cat A, Touyz RM. A new look at the renin-angiotensin system: Focusing on the vascular system. Peptides 2011; 32: 2141-2150.
20. Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, et al. Ras blockade with ARB and ACE inhibitors: Current perspective on rationale and patient selection. Clin Res Cardiol 2008; 97: 418-431.
21. Sun Y. Intracardiac renin-angiotensin system and myocardial repair/ remodeling following infarction. J Mol Cell Cardiol 2010; 48: 483-489.
22. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
23. Carey RM, Siragy HM. Newly recognized components of the reninangiotensin system: Potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24: 261-271.
24. Rouleau JL, de Champlain J, Klein M, Bichet D, Moyé L, Packer M, et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993; 22: 390-398.
25. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000; 101: 2981-2988.
26. Funakoshi S, Furukawa Y, Ehara N, Morimoto T, Kaji S, Yamamuro A, et al. Clinical characteristics and outcomes of Japanese women undergoing coronary revascularization therapy. Circ J 2011; 75: 1358-1367.